U.S., Oct. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07199179) titled 'Link Between Reduction of Suicide Ideation by Esketamine in Add-On and Initial Levels of Psychological Pain and Anhedonia' on Sept. 22.
Brief Summary: This study is looking at how intranasal esketamine (a nasal spray) can help reduce suicidal thoughts in patients with severe depression who are experiencing suicidal thoughts. Suicidal depression is a type of depression where people have active thoughts of suicide, which can be harder to treat with regular antidepressants. In fact, some people continue to have suicidal thoughts even after taking antidepressants.
Esketamine has already shown promise in helping reduce suicidal thoughts ...